Gelonghui, April 9丨Enhua Pharmaceutical (002262.SZ) held a performance briefing on April 8, 2024 to discuss “How much was the new drug R130 sold last year, and how much was the gross profit?” The company replied that the new drug oselidine injection (TRV130) launched by the company achieved sales of around 18 million yuan last year, and the gross margin was slightly higher than the company's anesthetic products.
恩华药业(002262.SZ)：新药奥赛利定注射液(TRV130)去年实现销售1800万元左右
Enhua Pharmaceutical (002262.SZ): The new drug Oselidine Injection (TRV130) achieved sales of around 18 million yuan last year
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.